Literature DB >> 20944650

Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.

Sylvie Bastuji-Garin1, Pascal Joly, Pauline Lemordant, Agnès Sparsa, Christophe Bedane, Emmanuel Delaporte, Jean-Claude Roujeau, Philippe Bernard, Jean-Claude Guillaume, Saskia Ingen-Housz-Oro, Hervé Maillard, Catherine Pauwels, Catherine Picard-Dahan, Yes Dutronc, Marie-Aleth Richard.   

Abstract

A rise in the incidence of bullous pemphigoid (BP) was documented recently in Europe, and the main risk factors for BP remain unknown. We conducted a multicenter case-control study to evaluate risk factors for BP. We identified 201 incident BP cases and 345 controls individually matched for age, gender, center, and place of residence (home, nursing home, or extended-care facility). We used univariate and multivariate logistic regression analyses to compare drugs used for over 3 months, comorbidities, and physical and cognitive impairments between cases and controls. Mean age of BP patients was 84.2 (±8.7) years. Factors independently associated with BP by multivariate analysis were major cognitive impairment (odds ratio (OR), 2.19; 95% confidence interval (95% CI), 1.24-3.87), bedridden condition (OR, 2.19; 95% CI, 1.23-3.89), Parkinson's disease (OR, 2.16; 95% CI, 1.09-4.27), unipolar or bipolar disorder (OR, 5.25; 95% CI, 1.21-22.86), and chronic use of spironolactone (OR, 2.30; 95% CI, 1.20-4.46) or phenothiazines with aliphatic side chains (OR, 3.70; 95% CI, 1.21-11.34). Chronic analgesic use was associated with a lower risk of BP (OR, 0.49; 95% CI, 0.30-0.81). Thus, risk factors for BP include neurological disorders, particularly dementia and Parkinson's disease, psychiatric disorders (unipolar and bipolar disorders), bedridden condition, and chronic use of several drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944650     DOI: 10.1038/jid.2010.301

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  58 in total

1.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Localised bullous pemphigoid overlying knee arthroplasty: a diagnostic challenge.

Authors:  Adam Truss; Stylianos Papalexandris; Susan Gardner; Robert Harvey
Journal:  BMJ Case Rep       Date:  2019-04-05

Review 3.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 4.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

Review 5.  Thyroid diseases and skin autoimmunity.

Authors:  Enke Baldini; Teresa Odorisio; Chiara Tuccilli; Severino Persechino; Salvatore Sorrenti; Antonio Catania; Daniele Pironi; Giovanni Carbotta; Laura Giacomelli; Stefano Arcieri; Massimo Vergine; Massimo Monti; Salvatore Ulisse
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

6.  Autoantibodies to Collagen XVII Are Present in Parkinson's Disease and Localize to Tyrosine-Hydroxylase Positive Neurons.

Authors:  Kelly A N Messingham; Samantha Aust; Joseph Helfenberger; Krystal L Parker; Susan Schultz; Julie McKillip; Nandakumar S Narayanan; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2015-12-14       Impact factor: 8.551

7.  [Bullous pemphigoid].

Authors:  F Schulze; M Kasperkiewicz; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2013-12       Impact factor: 0.751

Review 8.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

9.  A population-based study of the association between bullous pemphigoid and neurologic disorders.

Authors:  Katherine E Brick; Chad H Weaver; Rodolfo Savica; Christine M Lohse; Mark R Pittelkow; Bradley F Boeve; Lawrence E Gibson; Michael J Camilleri; Carilyn N Wieland
Journal:  J Am Acad Dermatol       Date:  2014-08-29       Impact factor: 11.527

10.  Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Authors:  Amy Attaway; Tracey L Mersfelder; Sakshi Vaishnav; Joanne K Baker
Journal:  J Dermatol Case Rep       Date:  2014-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.